Home › Research › Treatments
Selegiline in the treatment of mild to moderate Alzheimer-type dementia
Monteverde A, Gnemmi P, Rossi F, Monteverde A, Finali GC.. Clinical therapeutics, 1990-07-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Selegiline, an inhibitor of monoamine oxidase B, was tested on patients with mild to moderate dementia of the Alzheimer type. Its efficacy and tolerability were compared with that of phosphatidylserine in a randomized, single-blind, parallel fashion. Forty patients (24 men and 16 women) entered the trial. Selegiline was administered in 10-mg tablets once daily and phosphatidylserine in 100-mg capsules twice daily, both treatments lasting three months. Drug efficacy was assessed at baseline and then each month by means of an extensive battery of neuropsychological tests. The assessment of drug safety was based on monitoring for adverse drug reactions and on routine laboratory tests performed before and after treatment. At the end of the study the selegiline group showed improvements statistically significantly superior to those obtained in the phosphatidylserine group on most of the cognitive areas examined. Furthermore, of particular interest was the discovery, found only in the selegiline group, of an increased degree of autonomy in day-to-day activities. Tolerability was good, the only side effect reported in both groups being slight or moderate nausea, which was severe enough to warrant withdrawal from treatment only in one case, a patient in the selegiline group with a history of gastroduodenitis.
What this study adds
Evidence grade: High
This is a trial. Tolerability was good, with only slight or moderate nausea reported in both groups.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Monteverde, A., Gnemmi, P., Rossi, F., & Finali, G. C. (1990). Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clinical therapeutics.
Vancouver
Monteverde A, Gnemmi P, Rossi F, Finali GC. Selegiline in the treatment of mild to moderate Alzheimer-type dementia. Clinical therapeutics. 1990. PMID: 2121360.
BibTeX
@article{monteverde1990-2121360,
author = {Monteverde, A. and Gnemmi, P. and Rossi, F. and Finali, G. C.},
title = {{Selegiline in the treatment of mild to moderate Alzheimer-type dementia}},
journal = {Clinical therapeutics},
year = {1990},
pmid = {2121360}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Its efficacy and tolerability were compared with that of phosphatidylserine in a randomized, single-blind, parallel fashion.
- At the end of the study the selegiline group showed improvements statistically significantly superior to those obtained in the phosphatidylserine group on most of the cognitive areas examined.
Why it matters
In this three-month single-blind trial of 40 patients with mild to moderate Alzheimer-type dementia, selegiline produced significantly greater improvements on most cognitive tests than phosphatidylserine, and the selegiline group also showed increased autonomy in day-to-day activities. Tolerability was good, with only slight or moderate nausea reported in both groups.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 53/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 49 of the 92 points we could judge it on, which is 53 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Clinical therapeutics) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1990 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 52 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.4 citations a year over 38 year(s) since 1990 |
| Impact for its field and year | 3 / 6 | Cited 3.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Azienda Ospedaliero Universitaria Maggiore della Carita: institution h-index 227 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 2121360) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 49 / 92 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 49 of the 92 points we could judge it on is 53 out of 100. |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.